Special Report from The New England Journal of Medicine — Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
The dose-escalation dosing strategy represents an alternative approach for optimising
regorafenib dosing with comparable activity and lower incidence of adverse events
and could be implemented in clinical practice on the basis of these data.
This Review discusses the rapidly accumulating preclinical evidence in support of antitumour, but also of some pro-tumour, roles for γδ T cells in cancer progression. It also outlines the potential for manipulating their functions for use as an...
Ahmad Tarhini Md, PhD of the Winship Cancer Center discusses the United States Intergroup E1609 A phase III randomized study of adjuvant ipilimumab 3 or 10 mg kg versus high-dose interferon-α2b for resected high-risk melanoma.
Matthew S. Davids, MD, MMSc, discusses the significance of the findings from TRANSCEND CLL 004, a phase I/II trial investigating the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed or refractory chronic lymphocytic leukemia.